Meta AnalysisID 2427
免疫检查点抑制剂联合依托泊苷和铂类一线治疗广泛期小细胞肺癌：随机对照试验的贝叶斯网状Meta分析
CRD42020197226
The relative efficacy and safety of different immune checkpoint inhibitors combined with etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer.
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 2427
- Evidence Id
- 10985
- Core Evidence Id
- 10985
- Source Meta Analysis Id
- 2376
- Herb2 Meta Analysis Id
- HBMA002376
- Crd Id
- CRD42020197226
- Title
- Immune checkpoint inhibitors combined with etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: a bayesian network meta-analysis of randomized controlled trials
- Review Question
- The relative efficacy and safety of different immune checkpoint inhibitors combined with etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer.
- Study Type Included
- randomized controlled trials
- Condition Being Studied
- Small-cell lung cancer (SCLC), which is characterized by short doubling time, exceptional aggressiveness, high recurrence rate, accounts for ~15% of all subtypes of lung malignancy and two-thirds of initially diagnoses are extensive-stage SCLC (ES-SCLC). For the past three decades, etoposide plus either cisplatin or carboplatin, namely etoposide-platinum (EP), was the standard first-line therapy for ES-SCLC patients; however, the median progression-free survival and median overall survival of patients treated with first-line EP regimen were merely ~6 months and ~10 months, respectively. SCLC is considered as an immunogenic tumor because of the high tumor mutational burden (TMB) and TMB is positively correlated with the efficacy of immunotherapy. Additionally, immunotherapy combined with chemotherapy exerts synergistic anti-tumor effects. Immune checkpoint inhibitors (ICIs) targeting programmed cell death 1, programmed cell death ligand 1, and cytotoxic T lymphocyte-associated antigen-4 have shown remarkable clinical activity in relapsed or refractory ES-SCLC. Increasing studies with respect to different ICIs plus EP versus EP in first-line setting have emerged, but the relative comparisons among various combinations remain unclear. Therefore, we performed this systematic review and network meta-analysis to compare the efficacy and safety of different immuno-chemo combination strategies in the first-line treatment of untreated ES-SCLC.
- Participant
- patients with treatment-naive extensive-stage SCLC
- Animal
- Human Disease Modelled
- Intervention
- immune checkpoint inhibitors combined with etoposide and platinum as first-line treatment
- Comparator Control
- etoposide and platinum as first-line treatment
- Main Outcome
- Progression-free survival defined as the time from randomization to first progression (locoregional or distant) or death Measures of effect hazard ratio and correspondent 95% credible interval
- Outcome Measure
- Additional Outcome
- 1. Overall survival defined as the time from randomization until death from any cause; 2. Objective response rate, defined as the proportion of patients achieving an objective response 3. Grade 3-4 and grade 5 adverse events assessed according to National Cancer Institute Common Terminology Criteria for Adverse Events. Measures of effect hazard ratio and correspondent 95% credible interval for overall survival; odds ratio and correspondent 95% credible interval for objective response rate and adverse events
- Study Method
- Network meta-analysis, Systematic review
- Keyword
- Bayes Theorem; Etoposide; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Network Meta-Analysis; Platinum; Randomized Controlled Trials as Topic
- Contact
- Fei Chen [email protected]
- Organisational Affiliation
- The First Hospital of Jilin University http://www.jdyy.cn/
- Funding Source
- Jilin Provincial Department of science and technology (20170622011JC; 20180101009JC; 20190303146SF); Jilin Province Department of Finance (2018SCZWSZX-010); General Program of National Natural Science Foundation of China (81874052; 81672275).
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- 2020-07-06
- Registration Date
- 2020-08-06
- Anticipated Start Date
- 2020-06-11
- Anticipated Completion Date
- 2020-08-04
- Title Cn
- 免疫检查点抑制剂联合依托泊苷和铂类一线治疗广泛期小细胞肺癌：随机对照试验的贝叶斯网状Meta分析
- Title En
- Immune checkpoint inhibitors combined with etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: a bayesian network meta-analysis of randomized controlled trials
- Bilingual Status
- complete